Skip to main content
BTMD
NASDAQ Life Sciences

Biote Corp. Projects Significant EBITDA Decline for 2026 Amidst Large Share Repurchases

Analysis by Wiseek.aiReviewed by Editorial Team
Sentiment info
Neutral
Importance info
8
Price
$1.59
Mkt Cap
$51.358M
52W Low
$1.27
52W High
$4.75
Market data snapshot near publication time

summarizeSummary

Biote Corp. released an investor presentation detailing 2026 guidance, which includes a significant projected decline in Adjusted EBITDA, alongside a substantial $18.5 million share repurchase completed in January 2026.


check_boxKey Events

  • 2026 Financial Guidance Issued

    Biote Corp. projects 2026 revenue to be above $190 million and Adjusted EBITDA to be above $38 million.

  • Significant Projected EBITDA Decline

    The 2026 Adjusted EBITDA guidance of above $38 million represents a substantial decrease from $53.5 million reported in 2025.

  • Large Share Repurchase Completed

    The company paid $18.5 million in January 2026 to repurchase 6.1 million shares of Class V voting stock, following previous repurchases of 5.5 million shares for $25.1 million and 2.8 million shares for $12.5 million.

  • Ongoing Share Repurchase Program

    An $11.0 million balance remains in the Class A common stock repurchase program, with $3.4 million purchased in 2025.


auto_awesomeAnalysis

This 8-K filing, which includes an investor presentation, provides critical updates on biote Corp.'s financial outlook and capital allocation strategy. The company projects a significant decline in Adjusted EBITDA for 2026 compared to 2025, indicating operational headwinds. However, this comes alongside a substantial $18.5 million share repurchase completed in January 2026, representing a very large portion of the company's market capitalization. This aggressive capital return signals strong management confidence in the company's long-term value despite the weaker profitability outlook. Investors will need to carefully weigh the implications of the projected operational decline against the shareholder-friendly capital allocation decisions and strategic moves towards vertical integration.

At the time of this filing, BTMD was trading at $1.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.4M. The 52-week trading range was $1.27 to $4.75. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed BTMD - Latest Insights

BTMD
Apr 03, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
BTMD
Apr 02, 2026, 4:10 PM EDT
Filing Type: DEF 14A
Importance Score:
7
BTMD
Mar 13, 2026, 4:04 PM EDT
Filing Type: 10-K
Importance Score:
9
BTMD
Mar 11, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
8
BTMD
Mar 11, 2026, 4:07 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
BTMD
Jan 26, 2026, 5:21 PM EST
Filing Type: 8-K
Importance Score:
8